HDAC9 and diffuse large B-cell lymphoma: Fimepinostat, a first-in-class, dual-target inhibitor of phosphatidylinositol 3-kinase (PI3K) class I and pan-HDAC enzymes, achieved an ORR of 37% when administered as monotherapy in 25 participants with R/R DLBCL [79].